SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

KAZIA THERAPEUTICS LIMITED (KZA)

Listed on ASX

SHARE PRICES

Former (or subsequent) names

 FROMTO
KAZIA THERAPEUTICS LIMITED29/11/2017
NOVOGEN LIMITED13/05/199729/11/2017
NORVET LIMITED13/05/1997

Shareholder links

Our website ranking of KZA: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000KZA9
Address: Level 5, 20 George St, Hornsby, NSW, 2077Three International Towers Level 24, 300 Barangaroo Avenue Sydney NSW 2000
Tel:  + 61 2 9476 0344 Fax: + 61 2 9476 0388

Date first listed: 01/09/1994
Company Secretary: Kate Hill
Sector: Pharmaceuticals Biotechnology & Life Sciences Industry Group: XHJ
Activities: Kazia Therapeutics partners with the world's leading researchers and drug developers to bring forward a diversified portfolio of new cancer therapies

The suspension of trading in the securities of Kazia Therapeutics Limited will be lifted immediately, following the release by KZA of an announcement regarding a capital raising.

18/10/2018

The company completes a placement of KZA shares, primarily to sector-specialist institutional investors in Australia and internationally, at a price of A$0.38 per share. The placement will raise approximately A$3.4 million. Kazia will launch a share purchase plan to allow eligible existing holders of KZA securities the opportunity to acquire new fully-paid ordinary shares on the same terms as the placement. The SPP will open on Tuesday 23 October 2018.

18/10/2018

The securities of Kazia Therapeutics Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of KZA, pending the release of an announcement regarding a potential capital raising.

17/10/2018

name changed from Novogen Limited

29/11/2017

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    31/08/2020Steven Coffey13,526$1.067$14,432
    28/08/2020Bryce Carmine23,900$1.045$24,976
    27/08/2020James Garner25,000$1.018$25,450
    27/08/2020Iain Ross20,000$1.006$20,120
    25/05/2020Iain Ross125,000$0.411$51,325

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Iain RossNon Exec Chairman22/07/2015
    Mark HinzeCFO18/06/2010
    Bryce CarmineNon Exec Director03/06/2015
    Steven CoffeyNon Exec Director08/11/2012
    James GarnerExecutive Director, CEO01/02/2016

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    John O'ConnorNon Exec Chairman25/05/201208/06/2017
    Ian PhillipsNon Exec Director03/06/201508/06/2017
    Peter GunningNon Exec Director04/03/201405/09/2016
    Christopher CoxExecutive Director, CEO07/12/201222/07/2015
    Robert BirchDeputy Chairman, Non Exec Director12/12/201204/03/2014
    Andrew HeatonExecutive Director07/12/201204/03/2014
    Josiah AustinNon Exec Director20/09/201019/04/2013
    William RueckertChairman23/03/200907/12/2012
    Peter WhiteNon Exec Director20/09/201007/12/2012
    Ross YoungmanNon Exec Director20/09/201008/11/2012
    Peter ScuttNon Exec Director29/10/201025/05/2012
    Geoffrey LeppinusNon Exec Director24/02/200529/10/2010
    Philip JohnstonNon Exec Chairman01/01/199718/10/2010
    Christopher NaughtonManaging Director, CEO01/03/199701/12/2009

    Date of first appointment, title may have changed.